论文部分内容阅读
目的:探讨前列地尔联合依那普利对糖尿病肾病患者蛋白尿的影响。方法:在医院2015年7月到2016年9月期间诊治的糖尿病肾病患者中抽取92例作研究对象,遵从随机抽签原则予以分组,治疗组(n=46)应用前列地尔联合依那普利方案,对照组(n=46)单纯使用依那普利治疗,对比两组患者用药疗效、不良反应发生率以及治疗前后的尿微蛋白排泄率、尿蛋白含量变化。结果:(1)治疗组患者治疗总有效率是97.83%,高于对照组患者的82.61%(P<0.05);(2)治疗前,治疗组、对照组的尿微蛋白排泄率与尿蛋白含量组间比较有统计学差异(均P>0.01);治疗后,治疗组患者的尿微蛋白排泄率与尿蛋白含量均低于对照组(均P<0.01);(3)治疗组不良反应发生率是10.87%,与对照组的8.70%相比无统计学差异(P>0.05)。结论:前列地尔联合依那普利对糖尿病肾病患者蛋白尿有正性影响,可有效解除患者糖尿病肾病临床症状,并降低其尿微蛋白排泄率、尿蛋白含量,且不会增加患者不良反应,安全性较高,值得推广。
Objective: To investigate the effect of enalapril combined with alprostadil on proteinuria in patients with diabetic nephropathy. Methods: A total of 92 patients with diabetic nephropathy who were diagnosed and treated during the period from July 2015 to September 2016 in the hospital were enrolled in the study. Patients were divided into two groups according to the randomized drawing. The treatment group (n = 46) was treated with alprostadil Program, the control group (n = 46) simply enalapril treatment, the two groups were compared the efficacy of the drug, the incidence of adverse reactions and urinary protein excretion rate before and after treatment, urinary protein content changes. Results: (1) The total effective rate of treatment group was 97.83%, which was higher than 82.61% (P <0.05) of control group. (2) Before treatment, the urinary protein excretion rate and urinary protein (All P> 0.01). After treatment, the urinary protein excretion rate and urinary protein in the treatment group were lower than those in the control group (all P <0.01). (3) Adverse reactions The incidence was 10.87%, which was not significantly different from that of the control group (8.70%) (P> 0.05). Conclusion: AlprPrep rilapril combined with alprostadil has a positive effect on proteinuria in patients with diabetic nephropathy, which can effectively relieve the clinical symptoms of diabetic nephropathy and reduce its urinary protein excretion and urinary protein excretion without increasing adverse reactions , High security, it is worth promoting.